Biotech Stocks To Buy According To Matthew Strobeck’s Birchview Capital


After receiving a Ph.D. from the University of Cincinnati, Matthew Strobeck joined Birchview Capital in February 2014. With the goal of investing in undervalued growth opportunities, Birchview Capital was founded in 2012. SEC 13F filings for the third quarter revealed a US equities portfolio worth $146.96 million. At the time, the fund’s top 10 holdings accounted for nearly 70.43 percent of its total investments.

Here is Insider Monkey’s list of 10 biotech stocks to buy according to Matthew Strobeck’s Birchview Capital. Biotech company Acceleron Pharma Inc. specializes in developing, testing, and marketing new treatments. Protein misfolding and cell adhesion disorders are among the many diseases that can be treated with immunotherapies from Prothena Corporation Plc. EcoR1 Capital has the most stock in the company, at 11.28 million shares. In the biotechnology industry, United Therapeutics Corporation develops and commercializes treatments for people with chronic and life-threatening diseases. This is the first time a xenotransplanted organ has survived for more than two weeks after being transplanted into a human being. Albireo Pharma is a biotechnology company that specializes in the development of therapeutic medications for gastrointestinal disorders. From $79 to $80, HC Wainwright analyst Ed Arce has raised his price target for Albireo Pharmaceuticals. Hodgkin’s B-cell non-lymphoma treatment will be researched and commercialized by Biogen Inc. on February 1. As a result of recent events, the company is at a decision point. For more details, click 10 Biotech Stocks To Buy According To Matthew Strobeck’s Birchview Capital.